Hybrid
cell vaccination for cancer immune therapy: first clinical trial
with metastatic melanoma.
Uwe Trefzer, Guido Wengart,et al
Int. J. Cancer: 85, 618-626 (2000)
The
treatment of patients with disseminated malignant melanoma by vaccination
with autologous cell hybrids of tumor cells and dendritic cells.
Stefan W. Krause, Christine Neumann, et al
Journal of Immunotherapy: 25(5): 421-428 (2002)
Ex
vivo generation of human anti-melanoma autologous cytolic T cells
by dendritic cell/melanoma cell hybridomas.
Soruri A, Fayyazi A,
Cancer Immunol Immunotherapy: 50:307-314 (2001)
Hybrid
cell vaccination in metastatic melanoma: clinical and immunologic
results of a phase I/II study
Holger A. Haenssle, Stefan W. Krause, et al
J. Immunother. :27:147-155 (2004)
Generation
of dendritic cell-tumor cell hybrids by eletrofusion for clinical
vaccine application.
Katrina T. Trevor, Cathleen Cover, et al.
Cancer Immunol Immunother: 53:705-714 (2004)
Cell
fusion: an approach to generating constitutively proliferating human
tumor antigen-presenting cells.
P Jantscheff, G. Spagnoli, et al.
Cancer Immunol Immunother: 51:367-375 (2002)
Therapeutic
immune response induced by electrofusion of dendritic cells.
Hiroshi Tanaka, Keiji Shimizu, et al.
Cellular Immunlogy: 220: 1-12 (2002)
Tumour-dendritic
hybrid cell vaccination for the treatment of patients with malignant
melanoma: immunological effects and clinical results.
U Trefzer, G Herberth, K Wohlan, A Milling, M Thiemann, T Sharav,
K Sparbier, W Sterry, and P Walden
Vaccine. 2005; 23: 2367.
[MEDLINE Citation]
The
biological effects of syngeneic and allogeneic cytokine-expressing
prophylactic whole cell vaccines and the influence of irradiation
in a murine melanoma model.
Cancer Immunol Immunother. 2005; : 1.
Marie-Christine Labarthe, Nicole Halanek, Lindsay Birchall, Nick
Russell, Christiane Desel, Stephen Todryk, Marcus J Peters, Aisha
Lucas, Frank W Falkenberg, Angus G Dalgleish, Mike Whelan, and Stephen
John Ward
[MEDLINE Citation]
Therapeutic
Effectiveness of Recombinant Cancer Vaccines Is Associated with
a Prevalent T-Cell Receptor a Usage by Melanoma-specific CD8+ T
Lymphocytes
Cancer Res. 2004; 64:8068-8076.
Raffaele De Palma, Ilaria Marigo, Francesco Del Galdo, Carmela
De Santo, Paolo Serafini, Sara Cingarlini, Thomas Tüting, Julia
Lenz, Giuseppe Basso, Gabriella Milan, Paola Zanovello, and Vincenzo
Bronte
[Abstract]
[Full Text]
[PDF]
Competition Among Peptides in Melanoma Vaccines for Binding to
MHC Molecules.
J Immunother. 2004; 27: 425.
Lee W Thompson, Courtney F Garbee, Sarah Hibbitts, Laurence H
Brinckerhoff, Richard A Pierce, Kimberly A Chianese-Bullock, Donna
H Deacon, Victor H Engelhard, and Craig L Slingluff Jr
[MEDLINE Citation]
Melanoma vaccines.
Hosp Med. 2004; 65: 668.
B Elliott and A Dalgleish
[MEDLINE Citation]
[Establishment of mouse melanoma model expressing beta-galactosidase
and its application in the research of DNA vaccines against tumor]
Shi Yan Sheng Wu Xue Bao. 2004; 37: 339
GX Jin, XG Gong, Q Huang, and J Fei
[MEDLINE Citation]
Altered intracellular sorting signals do not influence the efficacy
of genetic melanoma vaccines incorporating helper determinants in
mice.
J Gene Med. 2004.
Jurgen Bruck, Julia Steitz, Dennis Strand, and Thomas Tuting
[MEDLINE Citation]
Individualized Synthetic Peptide Vaccines with GM-CSF in Locally
Advanced Melanoma Patients.
Cancer Biother Radiopharm. 2004; 19: 758.
J Atzpodien, M Fluck, and M Reitz
[MEDLINE Citation]
Heterogeneous antibody response to polyvalent melanoma vaccines
in syngeneic mice.
Cancer Immunol Immunother. 2005; 54: 345.
D Johnston and JC Bystryn
[MEDLINE Citation]
Melanoma vaccines: what we know so far.
Oncology (Huntingt). 2005; 19: 97.
JC Bystryn and SR Reynolds
[MEDLINE Citation]
T Regulatory Cell Depletion Can Boost DC-Based Vaccines.
Cancer Biol Ther, June 28, 2005; 4(6): .
Fabian Benencia and George Coukos
http://highwire.stanford.edu/cgi/medline/pmid;15917649
Emerging melanoma vaccines.
Expert Opin Emerg Drugs. 2005; 10: 393.
JC Bystryn and JL Rudolph
[MEDLINE Citation]
Autoimmune Toxicities Associated with the Administration of Antitumor
Vaccines and Low-Dose Interleukin-2.
J Immunother. 2005; 28: 412.
Kimberly A Chianese-Bullock, Elizabeth M H Woodson, Huimin Tao,
Scott A Boerner, Mark Smolkin, William W Grosh, Patrice Y Neese,
Priscilla Merrill, Gina R Petroni, and Craig L Slingluff Jr
[MEDLINE Citation]
Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides
evidence for immunological tolerance against authochthonous melanomas
in the skin.
Int J Cancer. 2005.
Julia Steitz, Stefanie Buchs, Damia Tormo, Aleix Ferrer, Jorg
Wenzel, Christoph Huber, Thomas Wolfel, Mariano Barbacid, Marcos
Malumbres, and Thomas Tuting
[MEDLINE Citation]
DNA vaccines for melanoma.
Cancer Chemother Biol Response Modif. 2005; 22: 761.
AD Cohen and JD Wolchok
[MEDLINE Citation]
Production and characterization of amplified tumor-derived cRNA
libraries to be used as vaccines against metastatic melanomas.
Genet Vaccines Ther. 2005; 3: 6.
Jean-Philippe Carralot, Benjamin Weide, Oliver Schoor, Jochen
Probst, Birgit Scheel, Regina Teufel, Ingmar Hoerr, Claus Garbe,
Hans-Georg Rammensee, and Steve Pascolo
[MEDLINE Citation]
Therapeutic vaccines for melanoma: current status.
BioDrugs. 2005; 19: 247.
MB Faries and DL Morton
[MEDLINE Citation]
Intranodal Administration of Peptide-Pulsed Mature Dendritic
Cell Vaccines Results in Superior CD8+ T-Cell Function in Melanoma
Patients
J. Clin. Oncol. 2003 21:3826-3835.
Isabelle Bedrosian, Rosemarie Mick, Shuwen Xu, Harvey Nisenbaum,
Mark Faries, Paul Zhang, Peter A. Cohen, Gary Koski, and Brian J.
Czerniecki
[Abstract]
Amplification of Virus-Induced Antimelanoma T-Cell Reactivity
by High-Dose Interferon-2b: Implications for Cancer Vaccines
Clin. Cancer Res. 2003 9:4347-4355.
Igor Astsaturov, Teresa Petrella, E. Umit Bagriacik, Mark de
Benedette, Robert Uger, Gail Lumber, Neil Berinstein, Ileana Elias,
Neill Iscoe, Caitlin Hammond, Paul Hamilton, and David E. Spaner
[Abstract]
Granulocyte-Macrophage Colony-Stimulating Factor-Based Melanoma
Cell Vaccines Immunize Syngeneic and Allogeneic Recipients via Host
Dendritic Cells
J. Immunol. 2003 171:5180-5187.
Achim Schneeberger, Petra Lührs, Raphaela Kutil, Peter Steinlein,
Hansjörg Schild, Walter Schmidt, and Georg Stingl
[Abstract]
Phase I/II study of treatment with dendritic cell vaccines in
patients with disseminated melanoma.
Cancer Immunol Immunother 5 Nov 2003.
Peter Hersey, Scott W. Menzies, Gary M. Halliday, Tam Nguyen,
Margaret L. Farrelly, Chitra DeSilva, and Margaret Lett
[MEDLINE Citation]
When Will Melanoma Vaccines Be Proven Effective?
Journal of Clinical Oncology December 2003
Jeffrey A. Sosman, Ashani T. Weeraratna, and Vernon K. Sondak
[Abstract]
Dissecting tumor responsiveness to immunotherapy: the experience
of peptide-based melanoma vaccines.
Biochim Biophys Acta 5 Dec 2003 1653(2): p. 61.
S Mocellin, CR Rossi, D Nitti, M Lise, and FM Marincola
[MEDLINE Citation]
Chemokine gene modification of human dendritic cell-based tumor
vaccines using a recombinant adenoviral vector.
Cancer Gene Ther 16 Jan 2004.
Alicia Terando, Blake Roessler, and James J Mule
[MEDLINE Citation]
Melanoma vaccines: achievements and perspectives.
Forum (Genova) 1 Jan 2003 13(2): p. 144.
VG Brichard and C G rard
When Will Melanoma Vaccines Be Proven Effective?
J. Clin. Oncol. 2004 22:387-389.
Jeffrey A. Sosman, Ashani T. Weeraratna, and Vernon K. Sondak
[Full Text]
[Reprint (PDF)]
Activation of Tumor-specific CD4(+) T Lymphocytes by Major Histocompatibility
Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy.
Cancer Res 1 Mar 2004 64(5): p. 1867.
SK Dissanayake, JA Thompson, JJ Bosch, VK Clements, PW Chen,
BR Ksander, and S Ostrand-Rosenberg
[MEDLINE Citation]
Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.
J Immunother 1 Jul 2004 27(4): p. 273.
MA Perricone, KA Smith, KA Claussen, MS Plog, DM Hempel, BL Roberts,
JA St George, and JM Kaplan
[MEDLINE Citation]
What is new in melanoma research? Vaccines, Basic and Translational
Research in 2003: report of a workshop at the Third Research Meeting
on Melanoma, Milan, Italy, May 2003.
Melanoma Res 1 Aug 2004 14(4): p. 241.
M Rescigno, A Testori, and G Parmiani
[MEDLINE Citation]
Gene-based vaccines and immunotherapeutics.
Proc. Natl. Acad. Sci. USA 27 August 2004.
Margaret Liu, Bruce Acres, Jean-Marc Balloul, Nadine Bizouarne,
Stephane Paul, Philippe Slos, and Patrick Squiban
[Abstract]
[PDF]
CpG motifs are efficient adjuvants for DNA cancer vaccines.
J Invest Dermatol 2004;123:371-9.
SCHNEEBERGER A, Wagner C, Zemann A, Luhrs P, et al.
http://amedeo.com/p2.php?id=15245438&s=mel
Delivery of interferon-alpha transfected dendritic cells into
central nervous system tumors enhances the antitumor efficacy of
peripheral peptide-based vaccines.
Cancer Res 2004;64:5830-8.
OKADA H, Tsugawa T, Sato H, Kuwashima N, et al.
http://amedeo.com/p2.php?id=15313927&s=mel
Heterogeneous antibody response to polyvalent melanoma vaccines
in syngeneic mice.
Cancer Immunol Immunother. 2004.
Dean Johnston and Jean-Claude Bystryn
[MEDLINE Citation]
Maturation Matters: Importance of Maturation for Antitumor Immunity
of Dendritic Cell Vaccines.
J Clin Oncol 2004;22 3834-3835.
Sylvia Adams, David O'Neill, and Nina Bhardwaj
http://www.jco.org/cgi/content/full/22/18/38344
Gene-based vaccines and immunotherapeutics.
Proc Natl Acad Sci U S A. 2004; 101 Suppl 2: 14567.
M Liu, B Acres, JM Balloul, N Bizouarne, S Paul, P Slos, and
P Squiban
[MEDLINE Citation]
Hybrid Cell Vaccination in Metastatic Melanoma: Clinical and
Immunologic Results of a Phase I/II Study.
J Immunother 1 Mar 2004 27(2): p. 147.
MR Parkhurst, JP Riley, PF Robbins, and SA Rosenberg
[MEDLINE Citation]
Activated natural killer cell-mediated immunity is required for
the inhibition of tumor metastasis by dendritic cell vaccination.
Exp Mol Med. 2004; 36: 428.
Ae Yung Kim1, Young Woock Noh1, Kwang Dong Kim1, Yong Suk Jang2,
Yong Kyung Choe1, and Jong Seok Lim1 3
[MEDLINE Citation]
Bone marrow-derived dendritic cell vaccination of dogs with naturally
occurring melanoma by using human gp100 antigen.
J Vet Intern Med. 2005; 19: 56.
S Gyorffy, JC Rodriguez-Lecompte, JP Woods, R Foley, S Kruth,
PC Liaw, and J Gauldie
[MEDLINE Citation]
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity
skin biopsies after dendritic cell vaccination correlates with clinical
outcome.
J Clin Oncol. 2005; 23: 5779.
IJ de Vries, MR Bernsen, WJ Lesterhuis, NM Scharenborg, SP Strijk,
MJ Gerritsen, DJ Ruiter, CG Figdor, CJ Punt, and GJ Adema
[MEDLINE Citation]
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced,
CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic
Melanoma.
Clin Cancer Res 2004;10 5381-5390.
Massimo Di Nicola, Carmelo Carlo-Stella, Roberta Mortarini, Paola
Baldassari, Anna Guidetti, Gian Francesco Gallino, Michele Del Vecchio,
Fernando Ravagnani, Michele Magni, Paul Chaplin, Natale Cascinelli,
Giorgio Parmiani, Alessandro M. Gianni, and Andrea Anichini
http://clincancerres.aacrjournals.org/cgi/content/abstract/10/16/5381